Elevations in Circulating sST2 Levels Are Associated With In-hospital Mortality and Adverse Clinical Outcomes After Blunt Trauma.

[1]  Y. Vodovotz,et al.  A conceptual time window‐based model for the early stratification of trauma patients , 2019, Journal of internal medicine.

[2]  Y. Vodovotz,et al.  Young and Aged Blunt Trauma Patients Display Major Differences in Circulating Inflammatory Mediator Profiles after Severe Injury. , 2019, Journal of the American College of Surgeons.

[3]  T. Billiar,et al.  Interleukin‐33 contributes to ILC2 activation and early inflammation‐associated lung injury during abdominal sepsis , 2018, Immunology and cell biology.

[4]  J. Lord,et al.  Prehospital immune responses and development of multiple organ dysfunction syndrome following traumatic injury: A prospective cohort study , 2017, PLoS medicine.

[5]  D. Pennington,et al.  Signatures of inflammation and impending multiple organ dysfunction in the hyperacute phase of trauma: A prospective cohort study , 2017, PLoS medicine.

[6]  Y. Vodovotz,et al.  IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model , 2017, PLoS medicine.

[7]  J. Routy,et al.  Plasma Level of Soluble ST2 in Chronically Infected HIV-1 Patients with Suppressed Viremia , 2017, The open AIDS journal.

[8]  T. Billiar,et al.  Role of the IL-33-ST2 axis in sepsis , 2017, Military Medical Research.

[9]  Mohsen Naghavi,et al.  US County-Level Trends in Mortality Rates for Major Causes of Death, 1980-2014. , 2016, JAMA.

[10]  Qi Mi,et al.  Individual-specific principal component analysis of circulating inflammatory mediators predicts early organ dysfunction in trauma patients. , 2016, Journal of critical care.

[11]  A. Peitzman,et al.  Elevated Admission Base Deficit Is Associated with a Complex Dynamic Network of Systemic Inflammation Which Drives Clinical Trajectories in Blunt Trauma Patients , 2016, Mediators of inflammation.

[12]  A. Peitzman,et al.  Computational Analysis Supports an Early, Type 17 Cell-Associated Divergence of Blunt Trauma Survival and Mortality* , 2016, Critical care medicine.

[13]  F. Liew,et al.  Interleukin-33 in health and disease , 2016, Nature Reviews Immunology.

[14]  P. Krijnen,et al.  Predictive value of cytokines for developing complications after polytrauma. , 2016, World journal of critical care medicine.

[15]  H. Turnquist,et al.  Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. , 2016, Blood.

[16]  Qi Mi,et al.  Insights into the Role of Chemokines, Damage-Associated Molecular Patterns, and Lymphocyte-Derived Mediators from Computational Models of Trauma-Induced Inflammation. , 2015, Antioxidants & redox signaling.

[17]  T. Macdonald,et al.  The IL-33/ST2 axis: Role in health and disease. , 2015, Cytokine & growth factor reviews.

[18]  H. Hanenberg,et al.  ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease , 2015, Science Translational Medicine.

[19]  G. Bandara,et al.  Activated mast cells synthesize and release soluble ST2‐a decoy receptor for IL‐33 , 2015, European journal of immunology.

[20]  M. Hur,et al.  Soluble ST2 Has a Prognostic Role in Patients With Suspected Sepsis , 2015, Annals of laboratory medicine.

[21]  D. Artis,et al.  IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin–EGFR interactions , 2015, Proceedings of the National Academy of Sciences.

[22]  A. Peitzman,et al.  Impact of Injury Severity on Dynamic Inflammation Networks Following Blunt Trauma , 2015, Shock.

[23]  F. Moore,et al.  Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. , 2015, Journal of advanced nutritional and human metabolism.

[24]  T. Mueller,et al.  Soluble ST2 in heart failure. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[25]  Zhiliang Gao,et al.  Soluble ST2 Plasma Concentrations Predict Mortality in HBV-Related Acute-on-Chronic Liver Failure , 2015, Mediators of inflammation.

[26]  Li Zhang,et al.  IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice , 2014, The Journal of allergy and clinical immunology.

[27]  H. Turnquist,et al.  IL-33 Is an Unconventional Alarmin That Stimulates IL-2 Secretion by Dendritic Cells To Selectively Expand IL-33R/ST2+ Regulatory T Cells , 2014, The Journal of Immunology.

[28]  P. Chu,et al.  Soluble ST2: A Novel Prognostic Biomarker of Heart Failure. , 2014, Acta Cardiologica Sinica.

[29]  M. Cohen.  Acute traumatic coagulopathy: clinical characterization and mechanistic investigation. , 2014, Thrombosis research.

[30]  N. Arsenijević,et al.  Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells , 2014, International journal of cancer.

[31]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[32]  T. Braun,et al.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. , 2013, The New England journal of medicine.

[33]  V. Bühren,et al.  Outcome after severe multiple trauma: a retrospective analysis , 2013, Journal of trauma management & outcomes.

[34]  B. Kronenberger,et al.  High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. , 2013, Translational oncology.

[35]  T. Osler,et al.  Outcomes of adult trauma patients admitted to trauma centers in Pennsylvania, 2000-2009. , 2012, Archives of surgery.

[36]  F. Liew,et al.  Interleukin-33 and the function of innate lymphoid cells. , 2012, Trends in immunology.

[37]  A. Peitzman,et al.  Racial disparities and sex-based outcomes differences after severe injury. , 2012, Journal of the American College of Surgeons.

[38]  K. Brohi,et al.  Acute traumatic coagulopathy , 2012, Current opinion in anaesthesiology.

[39]  John D. Storey,et al.  A genomic storm in critically injured humans , 2011, The Journal of experimental medicine.

[40]  Ashley M. Miller,et al.  IL‐33 induces skin inflammation with mast cell and neutrophil activation , 2011, European journal of immunology.

[41]  R. Tompkins,et al.  EARLY ELEVATION IN RANDOM PLASMA IL-6 AFTER SEVERE INJURY IS ASSOCIATED WITH DEVELOPMENT OF ORGAN FAILURE , 2010, Shock.

[42]  M. Mildner,et al.  Primary sources and immunological prerequisites for sST2 secretion in humans. , 2010, Cardiovascular research.

[43]  A. Nathens,et al.  The Attributable Mortality and Length of Stay of Trauma-Related Complications: A Matched Cohort Study , 2010, Annals of surgery.

[44]  David Díaz-Jiménez,et al.  Characterization of the novel ST2/IL‐33 system in patients with inflammatory bowel disease , 2010, Inflammatory bowel diseases.

[45]  F. Liew,et al.  Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection , 2010, Nature Medicine.

[46]  J. Januzzi,et al.  ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure , 2010, Current heart failure reports.

[47]  T. van der Poll,et al.  Soluble ST2 plasma concentrations predict mortality in severe sepsis , 2010, Intensive Care Medicine.

[48]  I. McInnes,et al.  Disease-associated functions of IL-33: the new kid in the IL-1 family , 2010, Nature Reviews Immunology.

[49]  T. van der Poll,et al.  Soluble ST2 Levels Are Associated with Bleeding in Patients with Severe Leptospirosis , 2009, PLoS neglected tropical diseases.

[50]  Dirk E. Smith,et al.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. , 2009, Arthritis and rheumatism.

[51]  Richard T. Lee,et al.  The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.

[52]  A. Rothman,et al.  Elevated levels of soluble ST2 protein in dengue virus infected patients. , 2008, Cytokine.

[53]  G. Franklin,et al.  Systemic inflammation after trauma. , 2007, Injury.

[54]  S. Tschoeke,et al.  Immunoparalysis after multiple trauma. , 2007, Injury.

[55]  M. Hayakawa,et al.  Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation* , 2007, Journal of Biological Chemistry.

[56]  B. Maier,et al.  EARLY VERSUS LATE ONSET OF MULTIPLE ORGAN FAILURE IS ASSOCIATED WITH DIFFERING PATTERNS OF PLASMA CYTOKINE BIOMARKER EXPRESSION AND OUTCOME AFTER SEVERE TRAUMA , 2007, Shock.

[57]  Javed Siddiqui,et al.  Circulating Cytokine/Inhibitor Profiles Reshape the Understanding of the SIRS/CARS Continuum in Sepsis and Predict Mortality1 , 2006, The Journal of Immunology.

[58]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[59]  S. Tominaga,et al.  Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. , 2005, Human molecular genetics.

[60]  Richard T. Lee,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction , 2004, Circulation.

[61]  A. Spittler,et al.  Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma , 2004, Intensive Care Medicine.

[62]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[63]  S. Tominaga,et al.  ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. , 2002, Biochemical and biophysical research communications.

[64]  S. Tominaga,et al.  Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. , 2001, American journal of respiratory and critical care medicine.

[65]  C. Sprung,et al.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.

[66]  R. Sauerwein,et al.  Cytokine Patterns in Patients After Major Vascular Surgery, Hemorrhagic Shock, and Severe Blunt Trauma Relation with Subsequent Adult Respiratory Distress Syndrome and Multiple Organ Failure , 1993, Annals of surgery.

[67]  L. Carey,et al.  Correlation of metabolic acidosis with outcome following injury and its value as a scoring tool , 1993, World Journal of Surgery.

[68]  J. Siegel,et al.  Oxygen debt and metabolic acidemia as quantitative predictors of mortality and the severity of the ischemic insult in hemorrhagic shock , 1991, Critical care medicine.

[69]  W. Haddon,et al.  The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. , 1974, The Journal of trauma.

[70]  A. Peitzman,et al.  Temporal Patterns of Circulating Inflammation Biomarker Networks Differentiate Susceptibility to Nosocomial Infection Following Blunt Trauma in Humans. , 2016, Annals of surgery.

[71]  M. Maegele.  Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options. , 2010, World journal of emergency medicine.

[72]  G. Lang,et al.  Increased soluble serum markers caspase‐cleaved cytokeratin‐18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD , 2009, Journal of clinical laboratory analysis.

[73]  I. Pallister.  Current concepts of the inflammatory response after major trauma: an update. , 2005, Injury.